Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for th

Indication
Symptomatic Neurogenic Orthostatic Hypotension; MSA - Multiple System Atrophy

Other upcoming events for TBPH

Patent ExpiryPatent/Exclusivity Expiry: YUPELRI

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Multi-center, Randomized Withdrawal and Long Term Extension Study of Ampreloxetine for th — TBPH Phase 3 Readout | BioSniper